Phase’s proprietary platform enables PDMS and other biocompatible materials to be 3D printed at a commercial scale and a previously unattainable resolution.
Our innovation creates microfluidics in industry-standard materials at a speed that propels bioinnovation across the biotech industry.
Phase's 3D printed microfluidics can include valves, sensors, and electrodes that are integrated during the printing process. Our proprietary technology yields a highly automated and reproducible process that allows for rapid customized iterations and scalable production.
Backed by two NIH grants, Phase, Inc. is currently working with Harvard Medical School, Georgia Tech, and Virginia Tech to develop a microfluidic device that will allow researchers to develop new brain cancer treatments.
With a team of seasoned leaders in both 3D printing and biomedical engineering with advanced degrees from MIT and UC Berkeley, Phase is poised to lead the microfluidics industry in unlocking the next wave of medical breakthroughs.
11148 Treynorth Drive, Suite A
Cornelius, North Carolina 28031